Dosing & Uses
Plaque Psoriasis
Pending FDA approval for moderate-to-severe plaque psoriasis
Next:
Pharmacology
Mechanism of Action
Humanized monoclonal IgG1 antibody that selectively inhibits interleukin-17A (IL-17A) and IL-17F
Interleukins are naturally occurring cytokines involved in normal inflammatory and immune responses and play a key role in the pathogenesis of plaque psoriasis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
